AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
methylhomatropine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| atropine derivatives | 1380 | 80-49-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK4,PRKDC,TEK,TGFBR1 | 19 | |||
| kinase-selectivity-class | EIF2AK3,GRK2 | 2 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 23, 1943 | FDA | ENDO PHARMS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A03BB06 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS BELLADONNA AND DERIVATIVES, PLAIN Belladonna alkaloids, semisynthetic, quaternary ammonium compounds |
| ATC | A03CB04 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS Belladonna and derivatives in combination with psycholeptics |
| CHEBI has role | CHEBI:48876 | muscarinic antagonist |
| CHEBI has role | CHEBI:49201 | anti-ulcer drug |
| CHEBI has role | CHEBI:53784 | antispasmodic drug |
Related Drugs by ATC class:
A03BB Belladonna alkaloids, semisynthetic, quaternary ammonium compounds 5 drugs
A03CB Belladonna and derivatives in combination with psycholeptics 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Irritable bowel syndrome | indication | 10743008 | DOID:9778 |
| Peptic ulcer | indication | 13200003 | DOID:750 |
| Cough | indication | 49727002 | |
| Brain damage | contraindication | 2470005 | |
| Tachyarrhythmia | contraindication | 6285003 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Dependent drug abuse | contraindication | 6525002 | |
| Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
| Alcohol withdrawal delirium | contraindication | 8635005 | |
| Asthenia | contraindication | 13791008 | |
| Severe chronic ulcerative colitis | contraindication | 14311001 | |
| Constipation | contraindication | 14760008 | DOID:2089 |
| Mood swings | contraindication | 18963009 | |
| Inflammatory bowel disease | contraindication | 24526004 | DOID:0050589 |
| Alcohol intoxication | contraindication | 25702006 | |
| Shock | contraindication | 27942005 | |
| Toxic megacolon | contraindication | 28536002 | DOID:1770 |
| Atony of colon | contraindication | 29479008 | |
| Hypercapnia | contraindication | 29596007 | |
| Dehydration | contraindication | 34095006 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
| Hypothyroidism | contraindication | 40930008 | DOID:1459 |
| Complete trisomy 21 syndrome | contraindication | 41040004 | DOID:14250 |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Low blood pressure | contraindication | 45007003 | |
| Achalasia of esophagus | contraindication | 45564002 | DOID:9164 |
| Chronic heart failure | contraindication | 48447003 | |
| Bradycardia | contraindication | 48867003 | |
| Paralytic ileus | contraindication | 55525008 | DOID:8442 |
| Peptic reflux disease | contraindication | 57643001 | |
| Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
| Drug AND/OR toxin-induced diarrhea | contraindication | 65979008 | |
| Substance abuse | contraindication | 66214007 | |
| Benign intracranial hypertension | contraindication | 68267002 | DOID:11459 |
| Urethral stricture | contraindication | 76618002 | |
| Spastic paralysis | contraindication | 78403003 | |
| Disturbance of salivary secretion | contraindication | 78948009 | |
| Decreased respiratory function | contraindication | 80954004 | |
| Injury of head | contraindication | 82271004 | |
| Cor pulmonale | contraindication | 83291003 | DOID:8515 |
| Hiatal hernia | contraindication | 84089009 | DOID:12642 |
| Pulmonary emphysema | contraindication | 87433001 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Acute abdominal pain | contraindication | 116290004 | |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Neoplasm of brain | contraindication | 126952004 | DOID:1319 |
| Seizure disorder | contraindication | 128613002 | |
| Autonomic dysreflexia | contraindication | 129618003 | |
| Bleeding | contraindication | 131148009 | |
| Drug-induced psychosis | contraindication | 191483003 | DOID:1742 |
| Myocardial dysfunction | contraindication | 233928007 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Bladder outflow obstruction | contraindication | 236645006 | |
| Morbid obesity | contraindication | 238136002 | DOID:11981 |
| Pyloric obstruction | contraindication | 244815007 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Retention of urine | contraindication | 267064002 | |
| Drowsy | contraindication | 271782001 | |
| Exacerbation of asthma | contraindication | 281239006 | |
| Lesion of brain | contraindication | 301766008 | |
| Coma | contraindication | 371632003 | |
| Primary adrenocortical insufficiency | contraindication | 373662000 | |
| Operation on gastrointestinal tract | contraindication | 386621005 | |
| Hypoxia | contraindication | 389086002 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Gastric ulcer | contraindication | 397825006 | DOID:10808 |
| Chronic lung disease | contraindication | 413839001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Central nervous system depression | contraindication | 418072004 | |
| Dysfunction of sphincter of Oddi | contraindication | 430887001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.82 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4018543 | VUID |
| N0000179152 | NUI |
| D02070 | KEGG_DRUG |
| 31610-86-3 | SECONDARY_CAS_RN |
| 4018543 | VANDF |
| CHEMBL1201235 | ChEMBL_ID |
| CHEMBL1200851 | ChEMBL_ID |
| C056244 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB00725 | DRUGBANK_ID |
| P97OGJ7L1L | UNII |
| 1546413 | RXNORM |
| 4831 | MMSL |
| 73112 | MMSL |
| 001725 | NDDF |
| 46668002 | SNOMEDCT_US |
| C3848532 | UMLSCUI |
| CHEBI:50373 | CHEBI |
| 5282592 | PUBCHEM_CID |
| 131 | INN_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Hydrocodone Bitartrate and Homatropine Methylbromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0121-1036 | SOLUTION | 1.50 mg | ORAL | NDA authorized generic | 29 sections |
| Hydromet | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0472-1030 | SOLUTION | 1.50 mg | ORAL | ANDA | 29 sections |
| Hydrocodone Bitartrate and Homatropine Methylbromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10702-055 | TABLET | 1.50 mg | ORAL | ANDA | 19 sections |
| Hydrocodone Bitartrate and Homatropine Methylbromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10702-150 | LIQUID | 1.50 mg | ORAL | ANDA | 20 sections |
| Hydrocodone Bitartrate and Homatropine Methylbromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 17856-0043 | SYRUP | 1.50 mg | ORAL | ANDA | 22 sections |
| Hydrocodone Bitartrate and Homatropine Methylbromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 17856-0455 | SYRUP | 1.50 mg | ORAL | ANDA | 27 sections |
| Hydrocodone Bitartrate and Homatropine Methylbromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 21695-869 | SYRUP | 1.50 mg | ORAL | ANDA | 23 sections |
| Hydrocodone Bitartrate and Homatropine Methylbromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 40032-118 | TABLET | 1.50 mg | ORAL | ANDA | 29 sections |
| Hydrocodone Bitartrate and Homatropine Methylbromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 40032-810 | SYRUP | 1.50 mg | ORAL | ANDA | 28 sections |
| Hydrocodone Bitartrate and Homatropine Methylbromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 43386-118 | TABLET | 1.50 mg | ORAL | ANDA | 28 sections |
| Hydrocodone Bitartrate and Homatropine Methylbromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50383-043 | SOLUTION | 1.50 mg | ORAL | ANDA | 32 sections |
| Hydrocodone Bitartrate and Homatropine Methylbromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-5168 | SYRUP | 1.50 mg | ORAL | ANDA | 23 sections |
| HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 59741-262 | SOLUTION | 1.50 mg | ORAL | ANDA | 33 sections |
| Hydrocodone Bitartrate and Homatropine Methylbromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 64950-206 | TABLET | 1.50 mg | ORAL | NDA authorized generic | 35 sections |
| Hydrocodone Bitartrate and Homatropine Methylbromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 64950-371 | SOLUTION | 1.50 mg | ORAL | NDA authorized generic | 35 sections |
| Hydrocodone Bitartrate and Homatropine Methylbromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 66336-871 | TABLET | 1.50 mg | ORAL | ANDA | 22 sections |